Malaysia’s health ministry welcomes medical cannabis clinical studies

WhatsAppWhatsAppFacebookFacebookTwitterTwitterPinterestPinterestRedditRedditGmailGmailShareShare

Last updated on August 3rd, 2022 at 12:31 pm

As there are currently no clinical trials being conducted on products containing cannabis extract for medical purposes, the Health Ministry in Malaysia welcomes applications to conduct clinical trials on these products. Deputy Health Minister Dr. Noor Azmi said on Thursday that such trials are not being carried out at this time, July 28th.

In response to a query from the Malaysian parliament, he stated that the Dangerous Drugs Act of 1952, the Poisons Act of 1952, and the Sale of Drugs Act of 1952 all make it possible for cannabis extract to be provided, imported, sold, and used for medical purposes, research, or clinical trials.

Also Read: The 10 Richest People in Malaysia

According to Dr. Azmi, businesses that are in possession of sufficient scientific evidence demonstrating the usefulness of products containing cannabis extract for medical purposes are eligible to make an application to the Drug Control Authority of Malaysia (DCA) in order to register those products.

According to the advertising, companies who have medicinal cannabis products that have been approved in other countries are eligible to submit an application in order to have their products registered and promoted in Malaysia.

Related Posts

These remarks were given in response to a query from Syed Saddiq Syed Abdul Rahman (Muda-Muar), who asked MoH to provide the most recent information regarding the legalization and use of medical cannabis in Malaysia.

“The MOH does not reject studies on the effectiveness of medical cannabis; it is time we follow the steps of 40 countries that have used it to treat diseases including cancer, depression, and epilepsy; we are ready to look at this,” he said in a statement.

According to Dr. Azmi, a proposal to separate the legal interpretations of cannabis, medical cannabis, and hemp will depend on the conclusions of the special committee that has been entrusted to research and establish the path of the industry’s development.

“Therefore the need to amend the Dangerous Drugs Act 1952 in connection with the control of cannabis and hemp, including creating separate interpretations for cannabis and hemp, depends on the Cabinet’s decision after reviewing the committee’s findings, taking into account the legal, socio-cultural, health, economy, Syariah law aspects and so on,” he further added to his statement.

Tags: Cannabis
Jasmine C.

Mabuhay! An upcoming Newswriter for the Asian Affairs from the Pearl of the Orient - Philippines. Avid follower of celebrity gossips, fashion news. I got into writing so that my fellow Kababayan will be constantly updated with the latest news.

Recent Posts

J-Pop Icon Aiko Returns With a ‘National Tour’ After 24 Months! What are her Stoppings & Shows?

One of the established and a leading Japanese singer and songwriter, Aiko is known for her blending of modern music…

July 15, 2025

EAFF E-1 2025: China vs Hong Kong! Who will end at the 3rd position?

Today, on 15 July 2025 it is going to be a clash of two equally potent football teams China and…

July 15, 2025

Japan Open 2025: Full Schedule, Indian Players, and Viewing Info

The badminton competition in Japan Open 2025 which is the second event on the BWF World Tour calendar has now…

July 15, 2025

Cal Raleigh Crowned Home Run Derby Champion After Dramatic Night in Atlanta

Seattle Mariners catcher Cal Raleigh was the 2025 winner of the MLB Home Run Derby on Monday night at Atlanta…

July 15, 2025

Korean Actress Kang Seo Ha Dies at Age 31 After Battling Illness

Kang Seo Ha, a South Korean actress passed away yesterday aged 31 and the South Korean entertainment industry is mourning.…

July 15, 2025

Indonesia U23 Squad Finalized for ASEAN U23 Cup 2025 in Jakarta

The Indonesian Football Federation has now officially settled on a 23-man list of competitors who will take part in the…

July 15, 2025